Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125147 | 0.87 | ALDH1A1 (0.58) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL3523467 | 0.87 | ALDH1A1 (0.58) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL11654599 | 0.82 | SMN1; SMN2 (0.60) | TSHRCYP3A4TDP1ALDH1A1HTT | |
| SCHEMBL2594596 | 0.81 | CYP3A4 (0.55) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL30092967 | 0.81 | CYP3A4 (0.55) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL10176626 | 0.79 | ALDH1A1 (0.62) | TSHRCYP3A4TDP1ALDH1A1HTT | |
| SCHEMBL446475 | 0.79 | TDP1 (0.55) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL2031510 | 0.78 | ALDH1A1 (0.52) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL397097 | 0.78 | SMN1; SMN2 (0.59) | TSHRCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL16951012 | 0.78 | SMN1; SMN2 (0.50) | TSHRCYP3A4TDP1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| EP-1351975-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TSHR 4635/4885CYP3A4 858/4885TDP1 103/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | TSHR 1243/4885CYP3A4 3990/4885TDP1 4242/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | TSHR 3229/4885CYP3A4 207/4885TDP1 799/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TSHR 4635/4885CYP3A4 858/4885TDP1 103/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | TSHR 2541/4885CYP3A4 67/4885TDP1 1883/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | TSHR 2541/4885CYP3A4 67/4885TDP1 1883/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | TSHR 397/4885CYP3A4 468/4885TDP1 4798/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | TSHR 3190/4885CYP3A4 385/4885TDP1 798/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | TSHR 4828/4885CYP3A4 4604/4885TDP1 1208/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | TSHR 3876/4885CYP3A4 3408/4885TDP1 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.